Quick Ratios
Quarterly Results
Profit & Loss
Balance Sheet
Cash Flow
Ratios
Mkt Cap
Market Capitalization
₹391Cr
Chemicals - Organic - Alcohol Based
Rev Gr TTM
Revenue Growth TTM
0.55%
Peer Comparison
Compare up to 10 companies side by side across valuation, profitability, and growth.

KANORICHEM
VS
| Quarter | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|
|
Growth YoY Revenue Growth YoY% | 17.8 | 3.8 | 2.6 | -11.3 | -18.8 | -4.2 | -52.5 | -47.2 | 19.4 | -47.6 | 18.8 | 47.4 |
| 422 | 391 | 365 | 339 | 333 | 382 | 176 | 165 | 414 | 183 | 204 | 246 |
Operating Profit Operating ProfitCr |
| 5.2 | 2.6 | 1.6 | 0.8 | 7.9 | 0.5 | 0.1 | 8.4 | 3.9 | 9.0 | 3.0 | 7.5 |
Other Income Other IncomeCr | 0 | 15 | 0 | 8 | 1 | 1 | 12 | 1 | -27 | 1 | 12 | 2 |
Interest Expense Interest ExpenseCr | 11 | 11 | 12 | 9 | 12 | 11 | 8 | 8 | 12 | 7 | 9 | 8 |
Depreciation DepreciationCr | 15 | 15 | 15 | 15 | 15 | 15 | 8 | 8 | 16 | 9 | 9 | 9 |
| -3 | 0 | -21 | -13 | 2 | -23 | -4 | 0 | -38 | 3 | 1 | 6 |
| -2 | 2 | -1 | 2 | 18 | 1 | 7 | 2 | 2 | 3 | 3 | 2 |
|
Growth YoY PAT Growth YoY% | -104.5 | -144.8 | -23.7 | -283.6 | -1,643.3 | -497.1 | 19.7 | -88.0 | -155.6 | 39.9 | 657.1 | 112.4 |
| -0.2 | -1.0 | -5.5 | -4.5 | -4.3 | -6.0 | -9.3 | -15.9 | -9.3 | -6.8 | 43.8 | 1.3 |
| -0.3 | -0.6 | -4.2 | -1.9 | -2.1 | -3.8 | -3.2 | -3.8 | -8.3 | -1.8 | 21.4 | 0.8 |
| Financial Year | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|
|
| -1.9 | 6.4 | 24.2 | 19.2 | 28.1 | -6.3 | 9.0 | 25.1 | 15.3 | -6.5 | 4.2 | -27.9 |
| 506 | 535 | 675 | 802 | 1,008 | 977 | 1,001 | 1,301 | 1,506 | 1,423 | 1,505 | 1,047 |
Operating Profit Operating ProfitCr |
| 4.6 | 5.3 | 3.8 | 4.1 | 5.9 | 2.8 | 8.6 | 5.0 | 4.6 | 3.5 | 2.0 | 5.5 |
Other Income Other IncomeCr | 27 | 17 | 7 | 45 | 7 | 22 | 8 | 29 | 10 | 19 | -20 | -12 |
Interest Expense Interest ExpenseCr | 9 | 14 | 20 | 24 | 36 | 37 | 32 | 27 | 36 | 43 | 46 | 35 |
Depreciation DepreciationCr | 30 | 34 | 45 | 47 | 49 | 56 | 58 | 57 | 59 | 59 | 63 | 43 |
| 13 | -1 | -32 | 10 | -15 | -43 | 11 | 13 | -12 | -31 | -97 | -28 |
| 1 | 6 | -8 | -2 | 5 | -11 | -5 | 11 | 1 | 21 | 12 | 11 |
|
| -63.9 | -158.4 | -229.4 | 148.8 | -268.5 | -61.8 | 150.7 | -86.0 | -676.9 | -301.4 | -110.9 | 138.0 |
| 2.3 | -1.3 | -3.4 | 1.4 | -1.8 | -3.1 | 1.5 | 0.2 | -0.8 | -3.5 | -7.1 | 3.7 |
| 2.8 | -1.6 | -5.4 | 3.2 | -3.4 | -5.9 | 3.3 | 1.6 | -2.0 | -8.8 | -19.1 | 12.1 |
| Financial Year | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|
Equity Capital Equity CapitalCr | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 |
| 472 | 581 | 558 | 566 | 577 | 547 | 565 | 577 | 584 | 579 | 499 | 510 |
Current Liabilities Current LiabilitiesCr | 242 | 259 | 291 | 365 | 412 | 404 | 375 | 409 | 509 | 509 | 571 | 351 |
Non Current Liabilities Non Current LiabilitiesCr | 230 | 344 | 330 | 319 | 374 | 389 | 391 | 392 | 366 | 364 | 416 | 225 |
Total Liabilities Total LiabilitiesCr |
Current Assets Current AssetsCr | 292 | 331 | 338 | 395 | 456 | 434 | 459 | 506 | 572 | 563 | 567 | 311 |
Non Current Assets Non Current AssetsCr | 690 | 893 | 872 | 883 | 945 | 940 | 903 | 897 | 909 | 928 | 932 | 797 |
Total Assets Total AssetsCr |
| Financial Year | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|
Operating Cash Flow Operating Cash FlowCr | 13 | 12 | 30 | 27 | 22 | 31 | 82 | 83 | 26 | 38 | 15 |
Investing Cash Flow Investing Cash FlowCr | -156 | -109 | 7 | -21 | -86 | -3 | -12 | -43 | -29 | -50 | -59 |
Financing Cash Flow Financing Cash FlowCr | 169 | 82 | -39 | -11 | 73 | -11 | -75 | -53 | 3 | 5 | 41 |
|
Free Cash Flow Free Cash FlowCr | -200 | -141 | -18 | -46 | -93 | -12 | 59 | 41 | -12 | -37 | -64 |
| 109.0 | -163.5 | -126.8 | 232.2 | -110.4 | -98.4 | 515.7 | 3,720.4 | -199.6 | -72.7 | -13.5 |
CFO To EBITDA CFO To EBITDA% | 54.5 | 39.1 | 113.1 | 77.6 | 33.8 | 110.4 | 88.1 | 121.9 | 35.5 | 71.9 | 46.8 |
| Financial Year | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|
Valuation Ratios Valuation Ratios |
Market Cap Market CapitalizationCr | 179 | 234 | 304 | 287 | 272 | 105 | 398 | 595 | 464 | 463 | 326 |
Price To Earnings Price To Earnings | 16.3 | 0.0 | 0.0 | 20.5 | 0.0 | 0.0 | 27.4 | 87.2 | 0.0 | 0.0 | 0.0 |
Price To Sales Price To Sales | 0.3 | 0.4 | 0.4 | 0.3 | 0.3 | 0.1 | 0.4 | 0.4 | 0.3 | 0.3 | 0.2 |
Price To Book Price To Book | 0.4 | 0.4 | 0.5 | 0.5 | 0.5 | 0.2 | 0.7 | 1.0 | 0.8 | 0.8 | 0.6 |
| 17.2 | 19.0 | 23.6 | 18.3 | 10.7 | 19.6 | 9.2 | 15.3 | 13.2 | 18.3 | 29.1 |
Profitability Ratios Profitability Ratios |
| 36.6 | 39.4 | 38.5 | 33.0 | 32.5 | 32.2 | 33.7 | 30.5 | 29.3 | 32.5 | 30.7 |
| 4.6 | 5.3 | 3.8 | 4.1 | 5.9 | 2.8 | 8.6 | 5.0 | 4.6 | 3.5 | 2.0 |
| 2.3 | -1.3 | -3.4 | 1.4 | -1.8 | -3.1 | 1.5 | 0.2 | -0.8 | -3.5 | -7.1 |
| 2.8 | 1.3 | -1.2 | 3.4 | 2.0 | -0.6 | 4.0 | 3.7 | 2.1 | 1.1 | -4.6 |
| 2.5 | -1.2 | -4.1 | 2.0 | -3.3 | -5.5 | 2.7 | 0.4 | -2.1 | -8.6 | -20.9 |
| 1.3 | -0.6 | -2.0 | 0.9 | -1.4 | -2.3 | 1.2 | 0.2 | -0.9 | -3.5 | -7.3 |
Operational Ratios Operational Ratios |
Solvency Ratios Solvency Ratios |
Liquidity Ratios Liquidity Ratios |
### **Overview**
Kanoria Chemicals & Industries Ltd. (KCIL) is an India-based diversified industrial group with a global footprint, operating through its parent entity in India and a network of subsidiaries and step-down subsidiaries across **Switzerland, Czech Republic, Germany, the United States, Canada, Ethiopia, and India**. The company operates in three core business segments: **Specialty & Industrial Chemicals**, **Automotive Electronics**, and **Textiles (Denim Manufacturing)**.
KCIL has embarked on a long-term growth strategy titled **"Vision2030"**, aimed at expanding existing product lines, launching new specialty chemicals, and improving global competitiveness through innovation, backward integration, and operational excellence.
---
### **Business Segments & Key Developments**
#### **1. Alco Chemicals Division (India)**
- **Products:** Formaldehyde, Pentaerythritol, Hexamine, Sodium Formate, Acetaldehyde, and Phenolic Resins.
- **End-User Industries:** Construction, Infrastructure, Paints, Pharmaceuticals, Agrochemicals, Wood Panel, and others.
- **Manufacturing Facilities:**
- Ankleshwar (Gujarat) – West Coast
- Vizag and Naidupet (Andhra Pradesh) – East Coast
- **Market Position:**
- Market leader in India for core products.
- Only **indigenous Indian manufacturer of Phenolic Resins** with dual-coast production capabilities since the commissioning of the Ankleshwar plant (FY 2022–23).
- Proprietary in-house technologies for **Pentaerythritol, Hexamine, and Phenolic Resins**, ensuring global cost and quality competitiveness.
- Formaldehyde plants use **advanced metal oxide and FORMOX technologies**, resulting in lower operating costs and higher purity.
- **Collaborations:**
Strategic partnerships with global leaders **Hexion Inc.** and **ASK Chemicals** enable production of high-value, customized phenolic resins.
- **Recent Capacity Expansions (Ankleshwar, Gujarat):**
- A **345 TPD Formaldehyde plant** was commissioned in August 2024, increasing total formaldehyde capacity to **1,400 TPD** across sites.
- An **18 TPD Hexamine plant** started commercial operations in September 2024, raising hexamine capacity to **52 TPD**.
- These expansions enhance backward integration and raw material security for downstream products.
- **Anti-Dumping Benefits:**
Imposition of anti-dumping duties on imported **Pentaerythritol** has improved domestic pricing and margins, strengthening FY2025 performance.
- **New Product Development (NPD):**
- The **NPD Cell** is advancing development of **Triacetin** and **Pentaerythritol derivatives**.
- A pilot plant for Triacetin is under testing, with plans for commercial-scale production upon success.
- Other exploratory products: **Paraformaldehyde, DNPT, and specialty resins**.
- **R&D Recognition:**
The **Ankleshwar R&D Center** is officially recognized by India’s Department of Scientific and Industrial Research (DSIR).
---
#### **2. Global Automotive Electronics & Control Systems (via APAG CoSyst Group)**
- **Structure:**
Operates through **APAG Holding AG** (Switzerland), a material subsidiary of KCIL, with step-down subsidiaries:
- APAG Elektronik AG (Switzerland)
- APAG Elektronik s.r.o. (Czech Republic)
- CoSyst Control Systems GmbH (Germany)
- APAG Elektronik LLC (USA)
- APAG Elektronik Corp (Canada)
- **Core Offerings:**
- Electronic Control Units (ECUs)
- Lighting systems (LED-based)
- Embedded software and hardware design
- Automation and in-house assembly line manufacturing
- ADAS (Advanced Driver Assistance Systems) subcomponents
- **Key Customers:**
Single-source supplier to major OEMs including:
- **Volkswagen Group (VW, Audi, Porsche)**
- **BMW Group (BMW, Mini, Rolls Royce)**
- **Stellantis, GM (Cadillac), Ford**
- Recent contract wins with **Tesla, Illinois Tool Works (ITW), MinebeaMitsumi, Sensirion**
- **Technology & Capabilities:**
- Technology-agnostic approach: supports both **ICE and EV platforms**.
- ISO 13485 certified; exploring entry into **medical devices** leveraging IEC 60601 compliance.
- Exceptional quality: achieved **3 ppm defect rate** in 2023–24.
- **Operational Restructuring & Strategic Shift (Sept 2025):**
- Due to volatility in the European auto sector and dual investment pressures (EV vs ICE), **APAG CoSyst underwent restructuring**.
- A **strategic investor** will inject capital for a **63% stake (subject to shareholder approval)**, while KCIL retains a **14.3% diluted equity interest**.
- Purpose: Strengthen capital base, improve agility, and retain long-term upside.
- **Revenue Outlook (2023–28):**
- 2023–24: ~CHF 90 million
- 2024–25 (est.): CHF 98 million
- 2025–26 (projected): CHF 111 million
- 2026–27: CHF 118 million
- 2027–28: CHF 127 million (based on awarded and probable contracts)
- **Production Optimization (Czech Republic):**
- Consolidated first-stage production in Czech facility (March 2024), with semi-finished goods shipped to Canada for final assembly.
- Expected benefits: Reduced inventory, lower procurement costs, improved working capital, and margin expansion by end of FY2024–25.
- **Market Challenges:**
- Geopolitical tensions (China-West) affecting Western OEM sales in China.
- OEMs insourcing production and demanding price cuts → margin pressure.
- Decline in ECU-focused R&D by OEMs.
- Ongoing semiconductor shortages in Canada led to temporary work reductions (Aug 2024), though supply chains are now normalizing.
---
#### **3. Denim Manufacturing – Kanoria Africa Textiles (KAT), Ethiopia**
- **Operations:**
Wholly owned subsidiary **Kanoria Africa Textiles PLC (KAT)** operates an integrated denim manufacturing unit in Ethiopia.
- **Operational Environment:**
- Severely impacted in earlier years by **foreign exchange shortages, civil unrest, and mandatory forex conversion policies**.
- Ethiopian Birr devalued sharply from **56 to 133 per USD (July 2024–March 2025)**, leading to large accounting distortions and foreign exchange losses.
- GDP of Ethiopia dropped from **USD 207 billion to USD 100 billion**, affecting national economic performance.
- **Financial Performance:**
- Revenue increased **21% in local currency (Birr)** in FY2024–25.
- Declined **31% in USD terms** due to devaluation.
- Difficult to compare year-on-year financials due to currency distortion.
- **Market Access:**
Domestic sales dominate due to foreign exchange restrictions on repatriation.
- **Recovery & Outlook (Nov 2025):**
- Gradual recovery underway.
- Improving macro conditions: IMF-backed reforms, move toward market-determined exchange rate.
- Enhanced operational efficiency and better cotton procurement due to improved working capital.
- Spinning unit operated at only 50% capacity (Aug 2022) due to delayed component deliveries; potential for near-term capacity expansion.
- USD 500,000–700,000 planned in technology upgrades to boost consistency and output.
---
### **Strategic Initiatives**
- **Vision2030 (Launched 2024–25):**
- Multi-year growth roadmap focusing on:
- Expansion of core chemicals.
- Diversification into **specialty and high-margin chemicals**.
- Geographical expansion and market development.
- Innovation through R&D and NPD.
- Investments planned:
- **INR 90 crore** for a 115,000 TPA Formaldehyde and 6,000 TPA Hexamine plant (Ankleshwar) – expected in Q3 FY25.
- **INR 30 crore** for a 7,000 TPA phenol-formaldehyde (PF) resin plant (completed in Q3 FY23).
- **Sustainability & Renewable Energy:**
- Operated a **5 MW solar power plant in Jodhpur (Rajasthan)**.
- Abandoned a proposed **183.16-acre solar project** in Jodhpur due to:
- Non-renewal of Power Purchase Agreement (PPA) with DISCOM.
- Collapse in Renewable Energy Certificate (REC) prices.
- Land now being sold to third-party developers.
- **Operational Excellence:**
- "Improvement Cell" implemented in 2020 to drive productivity and cost-saving initiatives.
- Engaged a **Big 4 consulting firm** (Sep 2023) to support cost optimization and efficiency improvements.